Market News

The license allows Mylan to develop fixed-dose combinations that offer the potential to treat all of the six major genotypes of hepatitis C virus.

The increase in diagnosed prevalent cases and the launches of interleukin (IL)-17 inhibitors, such as Eli Lilly’s Taltz and AstraZeneca’s Lumicef, will drive the market.

Domestic sales identified as chief driver behind unexpected rise in revenues.

It's anticipated that 65% of the total NSCLC market will go to immuno-oncology therapies.

Opdivo is now the first and only PD-1 inhibitor approved for a hematologic malignancy in the European Union.

Chase acquisition adds a new Phase III ready program for Alzheimer's disease to Allergan portfolio.

Pomalidomide available to people in England immediately via the Cancer Drugs Fund.

Many companies embracing alternative funding sources, such as angel investors, as investments from VC firms continue to decrease.

Studies suggest calcilytics may represent effective future asthma therapeutics.

The asthma and COPD treatment will be delivered using Vectura’s proprietary dry powder inhalation technology and device.

The company will create a cross-disciplinary Kendall Square campus, with teams spanning research, clinical development, medical affairs, business development and other related functions.

The type 2 diabetes treatment for adults will be delivered using SoloStar technology.

The XEN Glaucoma Treatment System reduces intraocular pressure in patients with refractory glaucoma.

Indication now includes use in children 6 months and older.

Grant will be used to tackle one of the biggest bioproduction problems currently facing the industry

Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive pain crises, a major complication of SCD with limited treatment options.

The OPTICORE coating technology allows targeted drug release in the large intestine to improve local and/or systemic drug bioavailability.

For patients this could mean more are able to achieve a normal life expectancy, without compromising on their quality of life.

Will coordinate and organize the company’s existing initiatives in sustainability and maximizing social impact, and its employee-driven community programs.

Therapeutic vaccines will increase the overall survival of poor-performance-status patients, and enable more rounds of treatments to be given, thus driving market growth.

Coating acts as an effective barrier to many of the extractables and leachables that can be released from the elastomer.

Treatment provides the opportunity for fewer infusion sites and shorter infusion durations.

Novo Nordisk’s N9-GP and CSL-Behring’s CSL-689 are expected to be launched in the forecast period and capture significant market share.

The acquisition reflects growing demand for the specialist packaging solutions for powders, minitabs or granules into stickpack sachets.

The spin-off of Bioverativ is on track to be completed in early 2017.

Titan Enterprises offers online informative and unbiased guidance document.

Two-thirds of pharmaceutical manufacturing is outsourced; preferred providers pick up largest share.

There are 90 pipeline cannabinoid products, including two in Phase III development.

The company’s insurance carrier will make a cash payment of $2.0 million to NRM.

Company prepares to start the production of sterile anti-infective injectable products at this site during 2018.

Avecia's Milford site is expected to be the largest cGMP oligonucleotide facility in the world.

Treatment combines two widely used and complementary medicines into a single daily injection for people with type 2 diabetes who are struggling to keep their blood sugar levels under control.

Treatment proven in a Phase III trial to significantly extend overall survival for patients with recurrent or metastatic squamous cell head and neck cancer.

New services to enable US biopharmaceutical companies to accelerate development of biosimilars.

Taytulla 1 mg/20 mcg will provide women with a new and effective option.

CDMO to invest in its facility in Hlohovec, Slovakia, to increase the scale at which it can perform wurster coating of the pellets.

Currently, there is no available drug that can treat the negative symptoms of schizophrenia, according to GlobalData.

Biologics and monoclonal antibodies to become a bigger presence within the small-molecule-dominated landscape.

GlobalData anticipates ALKS-5461 will enter the US market in early 2018.

Potential to be first submission of a proposed biosimilar trastuzumab in the US.

These shark antibodies are considered to have immediate and highly disease-specific potential for the diagnosis and treatment of Alzheimer’s disease.

Merger with sister company, C-Tech Electronics Ltd, to form a new vertically integrated manufacturing company.

Allows adult patients with advanced melanoma to receive first-line treatment with the potentially life-extending combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab) on the NHS in Scotland.

Merck is the first multinational enterprise to dedicate a large-scale green-field investment (€170 million) to the production of pharmaceuticals on China’s Essential Drug List.

Patent will cover a method of treating a subject having a viral infection caused by an influenza virus with neuraminidase inhibitors in combination with MEK inhibitors.

First early access scheme for breakthrough immunotherapy in blood cancer.

Provides access for patients and streamlined reimbursement.

Four dosage strengths of quetiapine fumarate extended release tablets being distributed.

TraceLink to present on global serialisation strategies at Pharmaceutical Serialisation & Traceability 2016.

As well as increasing output, the company is also investing in new technologies, including flow chemistry, chromatography and hydrogenation capabilities.

10 events to drive India’s rapid pharma growth predicted to reach $55bn by 2020.

Europe to be a key market for the company's phage-based therapies to treat bacterial infections in patients with unmet medical needs.

Amendments to the national immunization schedules of the US and the UK, the expansion of egg-based quadrivalent seasonal influenza vaccines across Germany, Italy, France, and Spain, and the transition from egg-based to cell culture-based vaccines will ...

MorphaBond is an abuse-deterrent formulation of extended release morphine using physical and chemical barriers, without the use of aversive agents or opioid antagonists.

Acquisition adds global rights to highly differentiated compounds to treat multi-factorial elements of NASH.

Gleevec recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx as Best Biotechnology Product.

Collaboration provides a comprehensive platform for data management, analysis and compound design in drug discovery.

A new delivery system for the nonly FDA-approved treatment to help patients produce more of their own tears.

Acquisition would expand Astellas' oncology pipeline with antibody in late-stage.

Products include an innovative Tool Management System and a new patented elliptical punch head form designed to increase dwell time on an existing table press without the need for time-consuming and expensive modifications.

The injection of capital follows an impressive year of growth for the company.

Award recognizes BMS for driving innovation in immuno-oncology.

Acquisition expands Allergan's gastroenterology pipeline.

The seminars discuss tablet design, tool material selection, tool features and configuration, tooling maintenance and lifecycle management.

Gamlen Tableting to demonstrate its new manufacturability protocol at AAPS.

First dedicated small-molecule manufacturing line to be constructed in Visp, Switzerland.

Pharmapack Awards 2017 closing: Calling all pharma packaging and drug delivery innovators.

New solutions for the packaging process.

Programs include a systematic approach to drug repurposing and data-driven, proactive chronic disease management - both fueled by the IBM Watson Health Cloud.

Provides pan-European availability of widely used and much needed oral liquid version clobazam tablets.

Investment reflects Amgen's commitment to serving patients by driving innovation and sustainable healthcare through technology discovery.

Approval is for first-line treatment of patients whose tumours have high PD-L1 expression with no EGFR or ALK genomic tumour aberrations.

Executives emphasised the importance of being first to market, two distinct outsourcing strategies, with biopharm and HPAPIs segments reporting strong growth.

The US will not only remain the largest major market for MDD drugs, but will extend its lead over other countries, says GlobalData.

Inflectra will be the first biosimilar monoclonal antibody (mAb) to be available in the US.

Keynote speaker says traditional monolayer cell culture models used to study tumour chemoresistance have proven to be woefully inadequate.

Propeller Health has developed a digital platform that integrates information from multiple sources and uses machine intelligence to recommend an optimal path therapy for individuals who suffer from COPD, asthma and other respiratory diseases.

Collaboration will focus on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets.

Will lead the company’s ongoing efforts to anticipate and act upon industry trends and technologies that may affect study sponsors, clinical sites, and patients, and to inform the development and delivery of current and future clinical supply services.

Sterinova to specialise in developing and manufacturing sterile ready-to-use injectable products.

The new facilities includes dedicated cell development suites and new robotic platforms for process automation.

The subscription deal, which is valued at a minimum of £500,000, provides partner access to Horizon's engineered cell lines.

Substantial rise can be attributed to increased drug consumption, caused by a rising disease burden, and government initiatives in the public healthcare sector.

Pre-filled syringes to be produced at Brussels, Belgium facility.

New database provides access to oncology studies in an effort to speed medicines to patients.

Extension of manufacturing plant will help meet worldwide demand for fertility and growth hormone disorder treatments.

Facilities chosen for their contributions to anti-infectives and vaccines.

Will become the largest GLP bioanalysis laboratory of its kind in the Nordic countries.

The addition of a roller compactor support's the company's recent capability extensions made in spray drying, Xcelodose technology, bi-layer tablets production and high-speed encapsulation.

Prize awarded for development of novel synthesis of Dronedarone intermediate.

The newest addition for 2017, the Pharmapack Start-up Hub, is designed to let innovative young pharma firms benefit from valuable networking and learning opportunities.

Postnova Analytics to host free 1-day seminar on advanced separation techniques.

Will include sharing information on industry trends and tooling expertise.

Can be used in a wide range of applications in upstream, downstream, and formulation and filling.

Cerbios will provide highly cytotoxic drug payloads and conjugation services for manufacture of ADC drug substance whereas Oncotec will provide sterile filling and lyophilization of cytotoxic active ingredients for ADCs.

Company's continued expansion allows it to further improve the transition of drug candidates from the discovery medicinal chemistry space through to formal regulatory based drug product development.

The studies have the potential to reveal novel insights for previously unknown autophagy signalling components, which could suggest rapid and innovative starting points for new drug treatments.

Approximately 30 members of staff will lose their job.

This substantial growth will primarily be driven by the growth of atypical antipsychotics, along with the increasing global diagnosed prevalence of MDD, and the potential introduction of six late-stage pipeline products.

Collaboration supports GLP toxicity studies and initiation of clinical development for treatment of Progressive Multifocal Leukoencephalopathy.

Is the first patent issued protecting the composition and method of use for Metablok, the company's drug candidate targeting inflammation, sepsis and cancer metastasis.

The new formulation will be offered in 4,000 lipase units capsule.

The UAE is quickly gaining popularity as a medical tourism destination due to its low costs, English-speaking medical staff, and virtually non-existent queues for treatment.

The terms of the settlement do not provide for any finding of wrongdoing on the part of Mylan Inc. or any of its affiliated entities or personnel.

Funding will allow the company to advance its research projects and move closer towards its goal of evaluating the efficacy of muco-regulatory drugs in patients.

Nyaditum resae targets to reduce the risk of developing the disease in people who carry the tuberculosis bacteria and those at risk of infection.

Will provide the central technical base for laboratory operations associated with the development and validation of manufacturing processes and analytical methods for the company’s products.

Sanofi Genzyme expects to submit a supplemental Biologics License Application to the FDA next year.

Company to start manufacturing in Brazil.

Cadence Acoustic Separator system is a novel single-use solution for the clarification of cell culture bioprocess fluids.

Although the market has recently been hit by the patent expirations of a number of the leading gastrointestinal products, the approval of new drugs, as well as rising prevalence, are expected to drive considerable growth. says GBI Research.

Eight new product lines and a fully integrated manufacturing and R&D site to transfer to Elanco, adding to its growing companion animal business.

Transaction is part of the European Commission’s anti-trust divestiture requirements arising from Teva’s acquisition of Allergan’s generics business.

Shire pleased with the decision and will continue to vigorously defend its patents.

Enables fully scalable, continuous multicolumn chromatography

New report compares the thermal performance and advantages of vacuum jacketed versus non-vacuum jacketed reaction vessels.

13 prestigious pharma leaders picked from 100 entries.

Investments being made ahead of anticipated demand.

Capabilities expanded across multiple locations in Europe.

Big data forecast to revolutionise pharma’s operations, everything from outsourcing thorough to drug discovery.